| Assessment Status | Assessment Process Complete |
| HTA ID | 19052 |
| Drug | Polatuzumab vedotin |
| Brand | Polivy® |
| Indication | In combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant (HSCT). |
| Assessment Process | |
| Rapid review commissioned | 03/12/2019 |
| Rapid review completed | 27/01/2020 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of polatuzumab vedotin (Polivy®) compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 26/02/2020 |
| Pre-submission consultation with Applicant | 31/03/2020 |
| Full submission received from Applicant | 10/07/2020 |
| Preliminary review sent to Applicant | 27/10/2020 |
| NCPE assessment re-commenced | 25/11/2020 |
| Factual accuracy sent to Applicant | 26/01/2021 |
| NCPE assessment re-commenced | 02/02/2021 |
| NCPE assessment completed | 16/02/2021 |
| NCPE assessment outcome | The NCPE recommends that polatuzumab vedotin (Polivy®) be considered for reimbursement if cost effectiveness can be improved relative to existing treatments.* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
The HSE has approved reimbursement following confidential price negotiations December 2021.
